Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.

Literature DB >> 6326666

In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.

Abstract

The in vitro susceptibilities of 393 recent clinical isolates to WIN 49375, a new quinolone derivative, were determined and concurrently tested with cefotaxime, tobramycin, and piperacillin. In general, members of the family Enterobacteriaceae were not as susceptible to tobramycin and piperacillin as they were to WIN 49375. Methicillin-resistant and -susceptible Staphylococcus aureus were equally susceptible to WIN 49375.

Entities: Chemical Species

Mesh：

Substances：

Year: 1984 PMID： 6326666 PMCID： PMC185523 DOI： 10.1128/AAC.25.3.377

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

6 in total

1. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors: K P Fu; H C Neu
Journal: Antimicrob Agents Chemother Date: 1978-03 Impact factor: 5.191

Review 2. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

Authors: R N Jones; C Thornsberry
Journal: Rev Infect Dis Date: 1982 Sep-Oct

3. Clinical efficacy of cefotaxime in serious infections.

Authors: P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal: Antimicrob Agents Chemother Date: 1982-01 Impact factor: 5.191

4. In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors: D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal: Antimicrob Agents Chemother Date: 1978-06 Impact factor: 5.191

5. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors: H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal: Antimicrob Agents Chemother Date: 1983-08 Impact factor: 5.191

6. Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.

Authors: K R Forward; G K Harding; G J Gray; B A Urias; A R Ronald
Journal: Antimicrob Agents Chemother Date: 1983-10 Impact factor: 5.191

6 in total

11 in total

1. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors: J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1986-02 Impact factor: 5.191

2. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors: J S Wolfson; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1985-10 Impact factor: 5.191

3. Quinolones: pharmacology.

Authors: L Verbist
Journal: Pharm Weekbl Sci Date: 1986-02-21

4. Metabolism and disposition of amifloxacin in laboratory animals.

Authors: J A Johnson; D P Benziger
Journal: Antimicrob Agents Chemother Date: 1985-05 Impact factor: 5.191

5. In vitro activities of amifloxacin and two of its metabolites.

Authors: R A Venezia; L A Prymas; A Shayegani; D M Yocum
Journal: Antimicrob Agents Chemother Date: 1989-05 Impact factor: 5.191

6. Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.

Authors: D Gargallo; M Moros; R Coll; M Esteve; J Parés; M A Xicota; J Guinea
Journal: Antimicrob Agents Chemother Date: 1988-05 Impact factor: 5.191

Review 7. Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors: R Janknegt
Journal: Pharm Weekbl Sci Date: 1986-02-21